Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with IP/IV Chemotherapy for Ovarian Cancer
NCT00588237Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2006
- Primary completion
- Nov 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in ovarian cancer, primary peritoneal carcinoma (PPC), fallopian tube cancer (PFTC), sponsored by Memorial Sloan Kettering Cancer Center. Started Aug 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00588237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00588237.